NMD Pharma launches an observational pilot study
NMD Pharma Initiated an observational pilot study investigating the effects of sarcopenia on neuromuscular transmission in the elderly
Aarhus, denmark, June 1 2021 – NMD Pharma A / S, a biotechnology company developing new therapies for neuromuscular disorders, today announces that it has launched a pilot observational study to assess whether sarcopenia, a condition characterized by loss of mass and function skeletal muscle aging is associated with neuromuscular junction (NMJ) transmission deficits in the elderly.
The US study will be led by Professor Brian Clark, PhD from Ohio University and Professor William David Arnold, MD, from Ohio State University Wexner Medical Center and will involve 16 subjects: eight people with sarcopenia over the age of 70. and eight healthy young people. and middle-aged individuals between the ages of 18 and 50. Subjects will undergo electrophysiological tests (repeated analyzes of nerve stimulation and single-fiber electromyography (EMG)) and various assessments of muscle mass (magnetic resonance imaging) and function (involving tests of muscle strength, power, fatigability and balanced).
NMD Pharma develops first-class small molecule inhibitors of the muscle-specific chloride ion channel, the ClC-1 ion channel, and has previously demonstrated that inhibition of ClC-1 can enhance neuromuscular transmission and ultimately skeletal muscle function . This study aims to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to determine whether these deficits correlate with reduced physical performance. These data will be used to inform potential future clinical trials of one of NMD Pharma’s ClC-1 inhibitors for the treatment of mobility limitations in sarcopenic individuals.
Thomas Holm Pedersen, Managing Directorr from NMD Pharma, said: “It’s the first clinical study coordinated by NMD Pharma in elderly people with sarcopenia. Investigators leading the study have already demonstrated NMJ transmission deficits are here in older mice, but if this translates into older human individuals is still aknown. We are grateful to the world-renowned Ohio clinical teams and their potential study participants for making this study possible. “
Professor Brian Clark, PhD, Ohio University commented: “The exact causes of sarcopenia are still unknown but Factors affecting muscle contraction strength regardless of mass, such as NMJ transmission, are increasingly suspected as contributors to the development of age-related physical disability. This study will seek to assesss this hypothesis and provide data that could lead to much needed clinical trials of this particular condition in the future. “
Professor William David Arnold, MD, of the Ohio State University Wexner Medical Center added: “Sarcopenia is a common condition in older people that contributes to functional decline, disability, fragility and falls and is one of the most important reasons for loss of independence in the elderly. There is a need to raise awareness of this condition in order to promote earlier detection and treatment and oneis such, it is vital that research in this area keep on going. WWe are happy to know more about this condition through this pilot study. “
NMD Pharma’s lead candidate, NMD670, is currently being evaluated in a combined Phase I / IIa trial to treat symptoms of myasthenia gravis (MG) taking place at the Center for Human Drug Research (CHDR) in Leiden , in the Nederlands.
Individuals in the Ohio region of the United States who are interested in learning more about participating in the Sarcopenia Study should contact Brian Clark at [email protected] or 740-593-2354.
NMD Pharma A / S
Thomas Holm Pedersen, CEO
Email: [email protected]
Strategic Communication Consilium
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
Email: [email protected]
Phone: +44 (0) 20 3709 5700
About NMD Pharma
NMD Pharma A / S, is a privately held biotechnology company, a leader in the development of new leading therapies for severe neuromuscular disorders. The company was incorporated as a spin-off from Aarhus University, Denmark, in 2015 and was founded on more than 15 years of research in muscle physiology with a focus on the regulation of excitability skeletal muscles during physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform harnessing the in-depth know-how of muscle physiology and muscle disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacological models to discover and develop proprietary modulators of neuromuscular function. NMD Pharma received seed funding from Novo Seeds, Lundbeckfonden Emerge and Capnova in 2016, and in 2018 raised EUR 38 million Series A funding, led by new investor INKEF Capital, with new investor Roche Venture Fund and existing investors Novo Seeds and Lundbeckfonden Emerge. To learn more about us online, visit http://www.nmdpharma.com/.
About the Ohio State University Wexner Medical Center
One of the nation’s leading academic health centers, Ohio State University’s Wexner Medical Center provides health care services in virtually all specialties and subspecialties of medicine. Thousands of patients come to us every month for treatments and services that they cannot find anywhere else. Access to health care information is at the heart of our research, education and patient care mission. At Ohio State Wexner Medical Center, we’re committed to improving health in Ohio and around the world through innovation in research, education, and patient care. Find out more about us online at www.wexnermedical.osu.edu
About Ohio University
Ohio University strives to be the best transformative, student-centered learning community in America, where students fulfill their promise, faculty advance knowledge, staff achieve excellence and the elders become world leaders. OHIO is committed to promoting, embracing and celebrating diversity in all its forms. Our Athens campus offers students a residency learning experience in one of the most picturesque academic settings in the country. Additional campuses and centers serve students statewide, and online programs further advance the University’s commitment to providing educational access and opportunities. Visit www.ohio.edu for more information. Ohio University is a research-intensive institution that has advanced knowledge through discovery and innovation in the natural and biomedical sciences, humanities and the arts, and engineering.
Sarcopenia is a syndrome characterized by progressive and widespread loss of skeletal muscle mass and strength and is strictly correlated with physical disability, poor quality of life, and death. Risk factors for sarcopenia include age, gender, and level of physical activity, although the exact causes of the disease are currently unknown. On average, it is estimated that 5 to 13% of people aged 60 to 70 have sarcopenia1.